JPMorgan downgraded Globant (GLOB) to Neutral from Overweight with a price target of $78, down from $108, following the Q2 report. Globant has to work to deliver positive growth in fiscal 2026 following the fiscal 2025 revenue guidance reduction, the analyst tells investors in a research note. The firm says its prior thesis of a premium growth and track record for Globant “appears challenged.” JPMorgan believes macro uncertainty and delayed client decision-making are catching up with the stock.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GLOB:
- Globant SA: Buy Rating Affirmed Amid Strong Pipeline and Innovative AI Strategy
- Globant SA Reports Strong Q2 2025 Earnings
- Closing Bell Movers: UnitedHealth jumps 10% as Berkshire, Appaloosa buy weakness
- Globant’s Q2 2025 Results Highlight Strategic AI Shift
- Globant sees FY25 adjusted EPS ‘at least’ $6.12, consensus $6.16.